<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>LA060189-0166</title>
	</head>
	<body>
		<main>
			<p><P> June 1, 1989, Thursday, Home Edition  </P> <P> FINANACIAL MARKETS;  </P> <P> AMGEN STOCK RISES SHARPLY ON FDA RUMOR  </P> <P> Amgen's stock climbed Wednesday in heavy trading on rumors that the Thousand  Oaks biotechnology company would receive Food and Drug Administration approval  today to sell its promising anti-anemia drug erythropoietin.  </P> <P> Amgen's stock rose $1.625 to close at $40.125 on volume of 462,000 shares  traded on the NASDAQ System.  </P> <P> Analysts have estimated the eventual size of the domestic market for EPO at  $450 million to more than $1 billion a year.  </P> <P> Richard Bock, biotechnology analyst for Sutro &amp; Co., said the widespread  rumor Wednesday was that FDA approval of EPO was imminent and "judging by the  price action on Amgen, that's what is most likely."  </P> <P> </P> <P> Engaged in Race  </P> <P> Amgen Chief Executive Gordon Binder said the FDA has called a press conference  today to announce its approval of a new drug. Binder would not comment on  whether EPO would be approved for sale.  </P> <P> Binder did say that both Amgen and FDA officials "have been working very hard,  including over the holiday weekend." EPO is Amgen's first commercial drug.  </P> <P> Amgen is in a race with Chugai-Upjohn, a Chicago biotechnology rival that has  submitted its own EPO application to the FDA.  </P></p>
		</main>
</body></html>
            